Terms ending in 2041
Bayer Pharma Aktiengesellschaft
Every in-force patent on Bayer Pharma Aktiengesellschaft's record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,905,270 | Carboxylic Acid Aromatic Amides as Antagonists of Bradykinin B1 Receptor In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 11,884,660 | A Substituted Oxopyridine Derivative In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 12,054,481 | Method for the Preparation of (4S)-4-(4-Cyano-2-Methoxyphenyl)-5-Ethoxy-2,8-Dimethyl-1,4-Dihydro-1-6-Naphthyridine-3-Carbox-AMIDE by Racemate Separation by Means of Diastereomeric Tartaric Acid Esters In force · High confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.